extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
entity-batch: update 1 entities
2026-03-16 12:45:25 +00:00 · 2026-03-16 12:45:21 +00:00 · 2026-03-16 12:43:53 +00:00
21 changed files with 25 additions and 28 deletions
--- a/domains/health/GLP-1
+++ b/domains/health/GLP-1
@ -35,12 +35,6 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti

 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.

-
-### Additional Evidence (extend)
-*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
-
-FLOW trial provides the strongest per-patient cost-savings mechanism for GLP-1s: preventing progression to dialysis ($90K+/year per patient). Slowing eGFR decline by 1.16 mL/min/1.73m2 annually could delay or prevent dialysis for many patients. CKD is among the most expensive chronic conditions to manage, making kidney protection the most economically favorable indication for the value-based care thesis, even if net costs remain inflationary through 2035 due to chronic use model.
-
 ---

 Relevant Notes:
--- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
+++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
@ -40,7 +40,7 @@ SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semagluti
 ### Additional Evidence (confirm)
 *Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*

-FLOW trial demonstrated simultaneous benefits: 24% reduction in kidney disease progression, 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89), and 18% lower risk of major cardiovascular events. The trial was designed as a kidney outcomes study but captured significant cardiovascular mortality benefits, demonstrating that organ protection effects compound across systems. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors.
+FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. This confirms multi-organ protection extends beyond the primary endpoint - a kidney trial produced substantial cardiovascular benefits. Additive benefits when used with SGLT2 inhibitors per separate Nature Medicine analysis.

 ---

--- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
+++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
@ -32,7 +32,7 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 ### Additional Evidence (confirm)
 *Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*

-FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope improvement of 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, providing the highest-quality evidence (NEJM publication, randomized controlled trial) for kidney protection.
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.

 ---

--- a/entities/internet-finance/metadao.md
+++ b/entities/internet-finance/metadao.md
@ -65,6 +65,7 @@ The futarchy governance protocol on Solana. Implements decision markets through
 - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)
 - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget
 - **2024-08-31** — Passed proposal to enter services agreement with Organization Technology LLC, creating US entity vehicle for paying contributors with $1.378M annualized burn rate. Entity owns no IP (all owned by MetaDAO LLC) and cannot encumber MetaDAO LLC. Agreement cancellable with 30-day notice or immediately for material breach.
+- **2024-03-19** — Colosseum proposed $250,000 OTC acquisition of META from treasury with TWAP-based pricing and 12-month vesting; proposal passed 2024-03-24
 ## Key Decisions
 | Date | Proposal | Proposer | Category | Outcome |
 |------|----------|----------|----------|---------|
--- a/inbox/archive/2024-00-00-alea-research-metadao-fair-launches.md
+++ b/inbox/archive/2024-00-00-alea-research-metadao-fair-launches.md
@ -4,7 +4,7 @@ title: "Alea Research: MetaDAO's Fair Launch Model Analysis"
 url: https://alearesearch.substack.com/p/metadaos-fair-launches
 archived_date: 2024-00-00
 format: article
-status: processing
+status: unprocessed
 processed_date: 2024-03-11
 extraction_model: claude-3-7-sonnet-20250219
 enrichments:
--- a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md
+++ b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md
@ -12,7 +12,7 @@ priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
 processed_by: vida
 processed_date: 2026-03-16
-enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 ---

@ -47,7 +47,9 @@ EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for
 ## Key Facts
 - FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
 - Median follow-up was 3.4 years before early stopping
- Primary composite endpoint showed HR 0.76 (P=0.0003) for major kidney disease events
+- Trial was stopped at prespecified interim analysis due to efficacy
+- Primary composite endpoint showed HR 0.76 (P=0.0003)
+- Cardiovascular death HR 0.71 (95% CI 0.56-0.89)
 - Annual eGFR slope difference was 1.16 mL/min/1.73m2 (P<0.001)
- Cardiovascular death HR was 0.71 (95% CI 0.56-0.89)
- Dialysis costs approximately $90,000+ per year per patient in the US
+- FDA expanded semaglutide (Ozempic) indications to include T2D patients with CKD
+- Additive benefits observed when used with SGLT2 inhibitors per Nature Medicine analysis
--- a/inbox/archive/2025-10-06-futardio-launch-umbra.md
+++ b/inbox/archive/2025-10-06-futardio-launch-umbra.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9kx7UDFzFt7e2V4pFtawnupKKvRR3EhV7P1Pxmc5XCQj"
 date: 2025-10-06
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-21-futardio-launch-forevernow.md
+++ b/inbox/archive/2026-02-21-futardio-launch-forevernow.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9FCpb4TmNkvrgkoiJzUm5vDBnQUqzSrUvxEvESBrns46"
 date: 2026-02-21
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-21-rakka-sol-omnipair-rate-controller.md
+++ b/inbox/archive/2026-02-21-rakka-sol-omnipair-rate-controller.md
@ -6,7 +6,7 @@ date: 2026-02-21
 archived_by: rio
 tags: [omnipair, rate-controller, interest-rates, capital-fragmentation]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-02-25-futardio-launch-donuts.md
+++ b/inbox/archive/2026-02-25-futardio-launch-donuts.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/DYKhWPc3fQTsMEg6xpKttiZFMRzr8EjkQzFPxQyVRUyt"
 date: 2026-02-25
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-25-oxranga-solomon-lab-notes-05.md
+++ b/inbox/archive/2026-02-25-oxranga-solomon-lab-notes-05.md
@ -6,7 +6,7 @@ date: 2026-02-25
 archived_by: rio
 tags: [solomon, YaaS, yield, audit, treasury, buyback, metadao-ecosystem]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-02-28-futardio-launch-salmon-wallet.md
+++ b/inbox/archive/2026-02-28-futardio-launch-salmon-wallet.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/512ifHxPFoZa2GUHXi4mLUvJkFfBcZp4E7d1A7Y6EpGG"
 date: 2026-02-28
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-02-futardio-launch-reddit.md
+++ b/inbox/archive/2026-03-02-futardio-launch-reddit.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/HkF8CWrUYcnCjGmdhaQ2jyqfwMWioNK7PrJiAxhQx9i8"
 date: 2026-03-02
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-03-pineanalytics-metadao-q4-2025-quarterly-report.md
+++ b/inbox/archive/2026-03-03-pineanalytics-metadao-q4-2025-quarterly-report.md
@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2028683377251942707
 date: 2026-03-03
 tags: [rio, metadao, futarchy, quarterly-report, financial-data]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-03-04-futardio-launch-lososdao.md
+++ b/inbox/archive/2026-03-04-futardio-launch-lososdao.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Aji1A3Fu6iBSh6kAysG9TR5o4cPB1RxzYwWqw8Xkbc5o"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md
+++ b/inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Gdyb1kNw26gve1VqU3zRxwZJhwJd5nAQ4goKNvAQBv9K"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-pli-crperie-ambulante.md
+++ b/inbox/archive/2026-03-04-futardio-launch-pli-crperie-ambulante.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/GmNzSXzQ3q6UCVRpBf8PkvEqoo454Qr6twWc9zuzJzBa"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-proph3t.md
+++ b/inbox/archive/2026-03-04-futardio-launch-proph3t.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/316rXWmR84ppwS4FKfZQWPmwqQCQi4NRWCbeVwYqDPna"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-05-futardio-launch-ludex-ai.md
+++ b/inbox/archive/2026-03-05-futardio-launch-ludex-ai.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/95HNkVuqzStFe7B6Aw32sgkbwkHEyEsA818izKKTz776"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-05-pineanalytics-futardio-launch-metrics.md
+++ b/inbox/archive/2026-03-05-pineanalytics-futardio-launch-metrics.md
@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2029616320015159504
 date: 2026-03-05
 tags: [rio, metadao, futarchy, futardio, permissionless-launches]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-03-09-rakka-omnipair-conversation.md
+++ b/inbox/archive/2026-03-09-rakka-omnipair-conversation.md
@ -6,7 +6,7 @@ title: "OmniPair deep dive — mechanism design, competitive position, ecosystem
 date: 2026-03-09
 ingested: 2026-03-11
 ingested_by: rio
-status: processing
+status: unprocessed
 domain: internet-finance
 transcript_path: "~/.pentagon/voicenotes/transcripts/rakka.md"
 claims_extracted: []
Author	SHA1	Message	Date
Teleo Agents	ba1ce0a01a	extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>	2026-03-16 12:45:25 +00:00
Teleo Agents	5c1fcdc341	entity-batch: update 1 entities - Applied 1 entity operations from queue - Files: entities/internet-finance/metadao.md Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>	2026-03-16 12:45:21 +00:00
Teleo Agents	a292518951	epimetheus: mark 14 zombies processed + reset 2 stuck processing sources Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>	2026-03-16 12:43:53 +00:00